In conclusion, in our present study, we found that IsoLiPro can lower USP11 protein levels both in vivo and in vitro, mainly through modulating protein degradation without impacting directly the USP11 enzyme activity, and consequently ameliorate AD pathologies in transgenic AD animal model. This evidence concerns the gene USP11 and Alzheimer disease.